Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

Breast Cancer Research and Treatment

Volumn 123, Issue 2, 2010, Pages 453-461

  Pritchard, Kathleen I ^a   Rolski, Janusz ^b   Papai, Zsuzsanna ^c   Mauriac, Louis ^d   Cardoso, Fatima ^e   Chang, Jose ^f   Panasci, Lawrence ^g   Ianuli, Carmen ^h   Kahan, Zsuzsanna ⁱ   Fukase, Kenjiro ^j   Lindemann, Justin P O ^j   MacPherson, Merran P ^j   Neven, Patrick ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c State Health Centre   (Hungary)

^d INSTITUT BERGONIÉ   (France)

^e JULES BORDET INSTITUTE   (Belgium)

^f RS McLaughlin Durham Regional Cancer Centre   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h Ianuli Med Consult   (Romania)

ⁱ UNIVERSITY OF SZEGED   (Hungary)

^j ASTRAZENECA   (United Kingdom)

^k UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

Advanced breast cancer; Endocrine; Faslodex; Fulvestrant; High dose; Loading dose

Indexed keywords

FULVESTRANT;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BRAIN ISCHEMIA; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE PAIN; JAPANESE; LOADING DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; WESTERN HEMISPHERE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CANADA; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN ANTAGONISTS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956164319     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1022-9     Document Type: Article

References (14)

1. AE Wakeling 2000 Similarities and distinctions in the mode of action of different classes of antioestrogens Endocr Relat Cancer 7 17 28 10.1677/erc.0.0070017 1:CAS:528:DC%2BD3cXktVyjs7k%3D 10808193
2. A Howell 2006 Fulvestrant ('Faslodex'): current and future role in breast cancer management Crit Rev Oncol Hematol 57 265 273 10.1016/j.critrevonc.2005. 08.001 16473018
3. A Howell JFR Robertson J Quaresma Albano, et al.. 2002 Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396 3403 10.1200/JCO.2002.10.057 1:CAS:528:DC%2BD38XntVyjsbs%3D 12177099
4. CK Osborne J Pippen SE Jones, et al.. 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 3386 3395 10.1200/JCO.2002.10.058 1:CAS:528:DC%2BD38XntVyjsbo%3D 12177098
5. JFR Robertson 2007 Fulvestrant (Faslodex)-how to make a good drug better Oncologist 12 774 784 10.1634/theoncologist.12-7-774 1:CAS:528: DC%2BD2sXpslertbg%3D 17673609
6. P Therasse SG Arbuck EA Eisenhauer, et al.. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
7. JF Robertson B Erikstein KC Osborne, et al.. 2004 Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer Clin Pharmacokinet 43 529 538 10.2165/00003088-200443080-00003 1:CAS:528:DC%2BD2cXlvFOlt7Y%3D 15170367
8. S Chia W Gradishar L Mauriac, et al.. 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 10.1200/JCO.2007.13.5822 1:CAS:528:DC%2BD1cXltlWhsrg%3D 18316794
9. JFR Robertson A Llombart J Rolski, et al.. 2009 Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study J Clin Oncol 27 4530 4535 10.1200/JCO.2008.21.1136 1:CAS:528:DC%2BD1MXhtlCns77J 19704066
10. Come SE, Parker LM, wulf G et al. (2009) Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings 27: (abstr 1050)
11. I Kuter R Hegg CF Singer, et al.. 2007 Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer Breast Cancer Res Treat 106 S7 (abstr 23)
12. A Di Leo G Jerusalem L Petruzelka, et al.. 2009 CONFIRM: a phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs. fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer Cancer Res 69 491s (abstr 25)
13. P McCormack F Sapunar 2008 Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer Clin Breast Cancer 8 347 351 10.3816/CBC.2008.n.040 1:CAS:528:DC%2BD1cXhtF2ru7rL 18757262
14. Sagara Y, Ohno S, Iwata H et al. (2009) Three dose regimens of fulvestrant in advanced breast cancer: results from a double-blind, comparative study (FINDER1). In: ASCO breast cancer symposium, San Francisco, CA, USA, October 8-10 (abstr 241)